Cite
HARVARD Citation
She, L. et al. (2019). Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. Lung cancer. pp. 88-94. [Online].